Preliminary Report on the Effect of Mesenchymal Stem Cell Therapy in Patients with Chronic Lung Allograft Dysfunction

Abstract

Lung transplantation is the best option of care for a variety of end-stage lung conditions no longer responding to standard options of medical or surgical care [1]. The most common causes of early morbidity and mortality after transplant include primary graft dysfunction [2], acute infectious complications [3], acute cellular rejection [4], or acute antibody-mediated rejection [5]. Long-term survival of lung transplant recipients is compromised by chronic lung allograft dysfunction (CLAD) [6], either obstructive (or bronchiolitis obliterans syndrome [BOS]) [7] or restrictive (restrictive allograft syndrome) [8].